(MENAFN- EIN Presswire)
Glaucoma Therapeutics Market
Rising glaucoma prevalence, drug development advancements, and increased eye health awareness are key factors driving the Glaucoma Therapeutics Market.
AUSTIN, TX, UNITED STATES, November 14, 2024 /EINPresswire / -- The Glaucoma Therapeutics
market is expected to witness significant growth at a CAGR of 5.83% from 2024 to 2032, reaching a value of USD 14.71 billion by 2032 and was valued at USD 8.85 billion in 2023.
Overview of the Glaucoma Therapeutics Market
The Glaucoma Therapeutics Market is experiencing substantial growth, driven by the rising prevalence of glaucoma, an eye condition that leads to optic nerve damage and, if untreated, blindness. Glaucoma is one of the leading causes of blindness globally, particularly among the elderly population, creating a significant demand for effective treatments. As the awareness surrounding eye health improves, more individuals are seeking treatment options, further propelling market growth.
In terms of drug supply, there has been an increase in the number of innovative drug treatments for glaucoma. Various therapeutic options, including prostaglandin analogs, beta-blockers, and combination drugs, are being utilized to manage intraocular pressure (IOP) effectively. The rise in personalized treatments and the development of novel drug formulations are also contributing to the growing demand in the market. The availability of treatments through online and retail pharmacies ensures that patients have easier access to medications.
Get a Sample Report of Glaucoma Therapeutics Market @
Prominent Players:
. Merck & Co. Inc
. Allergan
. Bausch & Lomb Incorporated
. Akorn Inc
. Teva Pharmaceuticals
. Oculis S.A.
. Alcon
. Santen
. Pfizer
. Nanodropper, Inc.
Segment Analysis
By Drug Class:
. Prostaglandins Analogs
. Beta Blockers
. Carbonic Anhydrase Inhibitors
. Alpha Adrenergic Agonists
. Combination Drugs
. Others
The Prostaglandin Analogs segment dominated the glaucoma therapeutics market, with prostaglandin analogs accounting for more than 42.3% of the market share in 2023. These drugs are preferred for their ability to effectively lower intraocular pressure (IOP) with fewer side effects compared to other drug classes. Beta Blockers segment holds the second-largest market share, with a growing demand for these drugs, particularly for their cost-effectiveness and long-standing presence in glaucoma treatment regimens.
The combination drugs segment is witnessing the fastest growth due to their ability to offer multiple mechanisms of action in a single drug, enhancing patient compliance and treatment efficacy. This segment is expected to grow at a CAGR of 6.5%.
By Disease Indication:
. Angle Closure Glaucoma
. Open Angle Glaucoma
. Others
The open-angle glaucoma segment dominated the market, accounting for over 69.8% of the market share. This is due to its higher prevalence compared to other forms of glaucoma. Although less common, the angle-closure glaucoma segment is expected to grow at a faster rate due to increasing awareness and better diagnostic technologies for identifying this condition early.
By Distribution Channel:
. Online Pharmacy
. Retail Pharmacy
. Hospital Pharmacy
The retail pharmacy segment held a major share of the market in 2023. This segment is supported by the increasing number of retail pharmacy outlets and their ability to provide timely access to glaucoma medications. With the rise of e-commerce and the increasing adoption of online pharmacies, this segment is growing rapidly, driven by the convenience and accessibility of purchasing glaucoma therapeutics online. Hospital pharmacies are also significant players in the market, particularly for patients requiring more complex treatments or those undergoing surgical interventions for glaucoma.
Buy Full Research Report on Glaucoma Therapeutics Market 2024-2032 @
Regional Analysis
North America was the dominant region in the Glaucoma Therapeutics Market, accounting for more than 37.2% of the market share in 2023. The region's leadership is attributed to a high prevalence of glaucoma, significant healthcare infrastructure, and advanced healthcare systems in countries like the United States and Canada. Furthermore, the growing number of pharmaceutical companies and the launch of innovative glaucoma therapeutics are further enhancing market growth in this region. Companies like Alcon, Glaukos, and Pfizer are expanding their presence in North America, launching advanced glaucoma treatments and fostering collaborations with research institutes to develop novel drug formulations.
Europe held the second-largest share of the glaucoma therapeutics market, with countries such as Germany, the UK, and France leading the demand for glaucoma treatments. Factors contributing to market growth include a growing elderly population and greater healthcare awareness about glaucoma prevention and management. The European market is expected to grow at a moderate pace, driven by increasing investments in research and development by pharmaceutical companies. In 2023, the approval of several new glaucoma medications and treatments in the European Union spurred market activity, leading to a surge in product availability.
Recent Developments in the Glaucoma Therapeutics Market
. In October 2023, Stuart Therapeutics and Glaukos entered a license agreement for the ST-113 drug candidate, which has shown potential for neuroprotection in glaucoma. The drug demonstrated neuroprotective capabilities for optic nerve axons in animal studies.
. In February 2022, Ocular Therapeutix reported interim Phase I data for OTX-TIC, a product candidate designed to reduce intraocular pressure (IOP) over long periods without affecting corneal health. The drug is currently undergoing Phase II trials for primary open-angle glaucoma and ocular hypertension in the U.S.
. In March 2022, Oculis S.A. and Accure Therapeutics announced a licensing agreement for ACT-01 (now OCS-05), a potential disease-modifying therapy for glaucoma. The drug has shown positive results in animal models for neuroprotective properties, with the companies working with regulatory agencies in the U.S., EU, and China.
. In August 2022, Alcon acquired Aerie Pharmaceuticals for USD 770 million, aiming to enhance its glaucoma drug portfolio. Aerie's two commercialized glaucoma products and its pipeline are expected to bolster Alcon's presence in the glaucoma therapeutics market.
. In January 2023, Allergan's new formulation of its popular glaucoma medication, Restasis, was approved by the FDA, offering an extended-release version aimed at improving patient adherence to therapy.
The Glaucoma Therapeutics Market is poised for significant expansion due to rising patient awareness, new drug innovations, and a growing global aging population. Key market players continue to focus on developing novel therapeutic solutions, with ongoing research and product launches promising an exciting future for the glaucoma therapeutics sector.
Speak with Our Expert Analyst Today to Gain Deeper Insights @
About Us:
S&S Insider is a global leader in market research and consulting, shaping the future of the industry. Our mission is to empower clients with the insights they need to thrive in dynamic environments. Utilizing advanced methodologies such as surveys, video interviews, and focus groups, we provide up-to-date, accurate market intelligence and consumer insights, ensuring you make confident, informed decisions.
Akash Anand
SNS Insider | Strategy and Stats
+1 415-230-0044
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN14112024003118003196ID1108886172